#NewAseBioMember | “Being a member of AseBio represents a great opportunity to increase our visibility within the biotechnology sector, both nationally and internationally”

AseBio. What does your company's work bring to the table and what is its strength?

Julio Alonso Babarro. Airway Shield represents a significant improvement in the way endotracheal intubation—a critical procedure in clinical practice—is performed. Through our device (the Airway Shield™), endotracheal intubation becomes faster, easier, and safer for both the patient and the healthcare professional. By reducing complications associated with this procedure, we not only help save lives but also contribute to lowering costs for healthcare systems.

Our main strength lies in the unique design of our device, which clearly sets it apart from existing solutions on the market. While other products focus solely on facilitating the insertion of the endotracheal tube, the Airway Shield™ not only properly guides the tube but also protects the patient from trauma associated with endotracheal intubation. This preventive, patient-safety- focused approach is what truly distinguishes us.

AseBio. What is AseBio for you?

Julio Alonso Babarro. For Airway Shield, being a member of AseBio represents a great opportunity to increase our visibility within the biotechnology sector, both nationally and internationally. We are currently at a pivotal moment, preparing for our international expansion, and being part of this community allows us to connect with specialized investors, access funding opportunities, and benefit from valuable institutional support in a highly competitive environment.

Additionally, being part of AseBio is also a way to join forces with other innovative companies and actively contribute to the development of the innovative and biotechnological ecosystem in Spain.

AseBio. When did you first hear about AseBio?

Julio Alonso Babarro. During the 'SILO AceleraBio' acceleration program, for which we were selected.

AseBio. What do you expect from being part of an association like AseBio?

Julio Alonso Babarro. Being part of AseBio will undoubtedly be an enriching opportunity. For us, it is a way to benefit from and learn from the collective knowledge of the sector, while also sharing our own insights—including both mistakes and successes—and experiences with other companies that are at similar stages of development.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Julio Alonso Babarro. In a highly competitive world like the biotechnology sector, one of the greatest challenges is breaking into highly specialized markets where competition is intense. Additionally, the adoption of new technologies involves a slow process due to the need to demonstrate strong clinical evidence, comply with strict regulations, and build trust among healthcare professionals.

In our case, this challenge is compounded by the need to change the mindset and practice surrounding a procedure that has been performed the same way for decades. Adapting professional habits requires education, training, tangible evidence—and a great deal of time.